Biotech Sector Sees Wave of Clinical and Regulatory Milestones Across Oncology and Neurology

Several biotech companies disclosed significant clinical, regulatory, and scientific developments on October 7, touching oncology diagnostics, drug delivery, and neurodegenerative disease.

Veraxa Biotech drew the sharpest market reaction, with shares rising 8.3% after the company reported that its lead BiTAC candidate demonstrated potent cancer-cell killing across 10 patient-derived non-small cell lung cancer models. Alongside that data, Veraxa announced it is embedding FDA-aligned New Approach Methodologies, known as NAMs, into its broader R&D strategy. The company said the consistent use of these human-relevant models could accelerate its BiTAC oncology pipeline and substantially reduce its reliance on animal testing.

Arrowhead Pharmaceuticals received entry into the FDA's STAR Pilot Program for plozasiran, its treatment for severe hypertriglyceridemia. The STAR program is designed to shorten the period between a complete supplemental new drug application submission and the FDA's action date, potentially accelerating a regulatory decision for plozasiran.

Arvinas shared novel oculomotor and biomarker data from a Phase 1 clinical trial of ARV-102 in Parkinson's disease patients, adding to the early clinical picture for its LRRK2-targeting degrader candidate. BillionToOne published peer-reviewed findings showing its tissue-free Northstar Response liquid biopsy achieved 94% concordance with tumor-informed ctDNA testing, with clinical ground truth in all discordant cases supporting the tissue-free result. Breathe BioMedical separately announced an expansion of its multi-center breast cancer clinical study into Nova Scotia.